Kennedy Capital Management, Inc. Coherus Bio Sciences, Inc. Transaction History

Kennedy Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.69 - $10.07 $170 - $302	-30 Reduced 0.01%	202,506 $1.6 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $1.45 Million - $2.81 Million	202,536 New	202,536 $1.95 Million
Q3 2018 Nov 14, 2018	SELL	$14.45 - $20.25 $1.26 Million - $1.77 Million	-87,248 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$10.25 - $17.45 $14,678 - $24,988	-1,432 Reduced 1.61%	87,248 $1.22 Million
Q1 2018 May 14, 2018	SELL	$9.1 - $13.7 $73,746 - $111,024	-8,104 Reduced 8.37%	88,680 $980,000
Q4 2017 Feb 13, 2018	SELL	$8.35 - $14.4 $10,253 - $17,683	-1,228 Reduced 1.25%	96,784 $852,000
Q3 2017 Nov 13, 2017	BUY	$11.1 - $14.5 $1.09 Million - $1.42 Million	98,012	98,012 $1.31 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.